Market Newsdesk

CONSHOHOCKEN, Pa.
, March 25, 2025 /PRNewswire/ — Quaker Houghton (the “Company”) (NYSE: KWR), the global leader in industrial process fluids, announced today that it has entered into a purchase agreement to acquire Dipsol Chemicals Co., Ltd., (“Dipsol”) a leading supplier of surface treatment and plating solutions and services primarily for the automotive and other industrial applications, for  23 billion JPY (~$153 million at current rates), subject to post-closing adjustments.  Dipsol is headquartered in Japan and operates globally with revenues of approximately $82 million over the twelve-month period ending December 31, 2024.  The purchase price represents a multiple of approximately 10.5x Dipsol’s trailing twelve month estimated adjusted EBITDA of approximately $15 million.

Joseph Berquist, Chief Executive Officer and President said, “The acquisition of Dipsol demonstrates our ability to use our strong financial position to make strategic investments that will accelerate growth and create shareholder value.  Dipsol provides Quaker Houghton with leading product technologies that complement our technical service model and add capabilities and breadth to our differentiated portfolio of advanced solutions.”

Dipsol was established in 1953 and is headquartered in Japan.  The company has a strong portfolio of products and services and a leading position in the Japanese market for plating chemicals.  Dipsol has approximately 450 employees worldwide, and a global presence with production and R&D facilities in Asia, North America, and Europe.

Mr. Berquist continued “Dipsol is a market leader, highly innovative and has an established market position and strong customer focus, especially in the Asia-Pacific region.  The acquisition will help expand our advanced solutions businesses in attractive end markets with solid growth characteristics and high barriers to entry.  Dipsol provides significant cross-selling capabilities and enhances our ability to meet and exceed the needs of our customers across the globe.”

The transaction is expected to close in the second quarter of 2025 and is subject to applicable regulatory approvals and certain other customary conditions.  Quaker Houghton expects to fund the purchase price for this acquisition with borrowings under its existing credit facility.

Non-GAAP Measure

The information in this press release includes non-GAAP (unaudited) financial information of Dipsol’s estimated adjusted EBITDA.  The Company believes this non-GAAP financial measure provides meaningful supplemental information as it enhances a reader’s understanding of the financial performance of Dipsol.  In addition, our definition of adjusted EBITDA may not be comparable to similarly named measures reported by other companies. The Company presents an estimated adjusted EBITDA for Dipsol, which is calculated as estimated EBITDA, which is calculated as estimated net income before depreciation and amortization, interest expense, net, and taxes on income before equity in net income of associated companies, plus or minus certain items that management believes are not indicative of future operating performance or not considered core to Dipsol’s operations. As it relates to future projections for Dipsol, as well as other forward-looking information contained in this press release, the Company has not provided guidance for comparable GAAP measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to determine with reasonable certainty the ultimate outcome of certain significant items necessary to calculate such measures without unreasonable effort. These items include, but are not limited to, certain non-recurring or non-core items Dipsol may record that could materially impact net income. These items are uncertain, depend on various factors, and could have a material impact on the U.S. GAAP reported results for the guidance period.

Forward-Looking Statements

This press release contains “forward-looking statements” that fall under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and the Securities Act of 1933, as amended. These statements can be identified by the fact that they do not relate strictly to historical or current facts. We have based these forward-looking statements on assumptions, projections and expectations about future events that we believe are reasonable based on currently available information, including statements regarding the potential effects of economic downturns; tariffs, including uncertainty surrounding changes in tariffs; inflation and global supply chain constraints on the Company’s business, results of operations, and financial condition; our expectation that we will maintain sufficient liquidity and remain in compliance with the terms of the Company’s credit facility; expectations about future demand and raw material costs; and statements regarding the impact of increased raw material costs and pricing initiatives. These forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, intentions, financial condition, results of operations, future performance, and business, which may differ materially from our actual results, including but not limited to the potential benefits of acquisitions and divestitures, the impacts on our business as a result of global supply chain constraints, and our current and future results and plans and statements that include the words “may,” “could,” “should,” “would,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “outlook, “target”, “possible”, “potential”, “plan” or similar expressions. Such statements include information relating to current and future business activities, operational matters, capital spending, and financing sources. A major risk is that demand for the Company’s products and services is largely derived from the demand for its customers’ products, which subjects the Company to uncertainties related to downturns in a customer’s business and unanticipated customer production slowdowns and shutdowns. Other major risks and uncertainties include, but are not limited to inflationary pressures, including increases in raw material costs; supply chain constraints and the impacts of economic downturns; customer financial instability; high interest rates and their impact on our and our customers’ business operations; the impacts from acts of war, terrorism and military conflicts, including those in Ukraine and the Middle East as well as economic, political and governmental actions taken by various governments and governmental organizations in response; economic and political disruptions particularly in light of numerous elections globally and the possibility of regime changes; the possibility of economic recession; legislative and regulatory developments including changes to existing laws and regulations, or the way they are interpreted, applied or enforced; tariffs, trade restrictions, and the economic and other sanctions imposed by other nations on Russia and Belarus and/or other government organizations; suspensions of activities in Russia by many multinational companies; foreign currency fluctuations; significant changes in applicable tax rates and regulations; future terrorist attacks and other acts of violence; the impacts of consolidation in our industry, including loss or consolidation of a major customer, the effects of climate change, fires, or other natural disasters; and the potential occurrence of cyber-security breaches, cyber-security attacks and other technology outages and security incidents. Furthermore, the Company is subject to the same business cycles as those experienced by our customers in the steel, automobile, aircraft, industrial equipment, aluminum and durable goods industries. Our forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its operations that are subject to change based on various important factors, some of which are beyond our control. These risks, uncertainties, and possible inaccurate assumptions relevant to our business could cause our actual results to differ materially from expected and historical results. All forward-looking statements included in this press release, including expectations about business conditions during 2024 and future periods, are based upon information available to the Company as of the date of this press release, which may change. Therefore, we caution you not to place undue reliance on our forward-looking statements. For more information regarding these risks and uncertainties as well as certain additional risks that we face, refer to the Risk Factors section, which appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent reports filed from time to time with the Securities and Exchange Commission. We do not intend to, and we disclaim any duty or obligation to, update or revise any forward-looking statements to reflect new information or future events or for any other reason. This discussion is provided as permitted by the Private Securities Litigation Reform Act of 1995. 

About Quaker Houghton

Quaker Houghton is the global leader in industrial process fluids. With a presence around the world, including operations in over 25 countries, our customers include thousands of the world’s most advanced and specialized steel, aluminum, automotive, aerospace, offshore, container, mining, and metalworking companies. Our high-performing, innovative and sustainable solutions are backed by best-in-class technology, deep process knowledge and customized services. With approximately 4,400 employees, including chemists, engineers and industry experts, we partner with our customers to improve their operations so they can run even more efficiently, even more effectively, whatever comes next. Quaker Houghton is headquartered in Conshohocken, Pennsylvania, located near Philadelphia in the United States. Visit quakerhoughton.com to learn more.

View original content to download multimedia:https://www.prnewswire.com/news-releases/quaker-houghton-expands-advanced-solutions-portfolio-through-its-acquisition-of-dipsol-chemicals-302410474.html

SOURCE Quaker Houghton

• Initiated IND-enabling toxicology program
• IND submission planned for 4Q25; Clinical data expected in 1H26

CRANBURY, N.J.
, March 25, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug Administration (FDA) has granted “orphan drug” designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor (LEPR) deficiency, including obesity caused by this condition.

“This FDA orphan designation is a key step in developing Palatin’s MC4R receptor agonists for rare obesity conditions,” said Carl Spana, Ph.D., President and CEO of Palatin. “Currently, the only FDA-approved treatment for obesity due to leptin receptor deficiency is a daily injection. PL7737’s oral form could provide a more convenient and effective option for these patients and others with rare genetic obesity disorders. We are also exploring PL7737 for hypothalamic obesity and plan to begin a Phase 1 SAD/MAD study in late 2025.”

Dr. Spana continued, “Statistical analysis is now complete for our Phase 2 BMT-801 clinical study of the co-administration of MC4R bremelanotide + GLP-1/GIP tirzepatide for the treatment of obesity, and for our Phase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis. We look forward to releasing topline data results for both of these studies later this month.”

Obesity caused by LEPR deficiency is a rare genetic condition where mutations in the LEPR gene disrupt MC4R signaling. The Leptin-Melanocortin pathway in the hypothalamus plays a key role in regulating hunger, energy storage, and body weight. People with this condition experience extreme, constant hunger from a young age, leading to severe early-onset obesity. PL7737, an MC4R agonist, is designed to restore impaired signaling caused by these genetic mutations.

Supporting the development and evaluation of new treatments for rare diseases is a key priority for the FDA. The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including:

• Tax credits for qualified clinical trials
• Exemption from user fees
• Potential seven years of market exclusivity after approval

Sponsors seeking orphan drug designation for a drug must submit a request for designation to the agency. Sponsors requesting designation of the same drug for the same rare disease or condition as a previously designated product must submit their own data and information to support their designation request. Orphan drug designation is a separate process from seeking approval or licensing. Drugs for rare diseases go through the same rigorous scientific review process as any other drug for approval or licensing.

About Melanocortin-4 Receptor Agonists Effect on Obesity

Hypothalamic neurons expressing the melanocortin-4 receptor (MC4R) play a central role in regulating stored energy, food intake, and body weight. Genetic mutations that inhibit signaling through the MC4R pathway lead to hyperphagia, decreased energy expenditure and early-onset obesity; such mutations have been identified as the cause of several rare genetic obesity disorders. MC4R agonism represents an attractive target for potential obesity treatments.

About Melanocortin Receptor Agonists

The melanocortin receptor (“MCR”) system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about Palatin products in development, clinical trial results, potential actions by regulatory agencies, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin’s actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin’s ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin’s products, and other factors discussed in Palatin’s periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.

Palatin Technologies^® is a registered trademark of Palatin Technologies, Inc.

^{__________________
1} Huvenne H, Duberne B, Clément K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9(3):158-173.
² Ellacott KL, Cone RD. The role of the central melanocortin system in the regulation of food intake and energy homeostasis: lessons from mouse models. Philos Trans R Soc Land B Biol Sci. 2006;361(1471):1265-1274.
³ Ayers KL, Glicksberg BS, Garfield AS, et al. Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 2018;103(7):2601-2612.
⁴ Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC variants in humans. Nat Genet. 1998;19(2):155-157.

View original content to download multimedia:https://www.prnewswire.com/news-releases/palatins-oral-mc4r-agonist-pl7737-receives-fda-orphan-drug-designation-for-obesity-due-to-leptin-receptor-deficiency-302409657.html

SOURCE Palatin Technologies, Inc.

Broader protection induced by combination of COVID adenovirus vaccine plus CiVax
™ compared to 2-shot mRNA vaccination series

PRINCETON, N.J.
, March 25, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of CiVax™, a thermostabilized subunit vaccine against SARS-CoV-2. Using custom-developed immunoassays, the combination of a primary adenovirus vaccine (COVID-19 Vaccine AstraZeneca) coupled with a CiVax™ booster was shown to induce broader protection against COVID-19 variants in non-human primates than a 2-shot mRNA series (such as the Moderna vaccine Spikefax^® or the Pfizer vaccine Cominarty^®) in humans. In collaboration with Axel Lehrer, PhD, Professor at the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaiʻi at Mānoa, the manuscript entitled “Use of a Multiplex Immunoassay Platform to Investigate Multifaceted Antibody Responses in SARS-CoV-2 Vaccinees with and Without Prior Infection”, has been published in COVID.

“The CiVax™ vaccine has demonstrated broad and robust immune responses in mice, which has been recapitulated in NHPs and further shown to yield protection against infection with COVID-19 variants of concern,” stated Dr. Lehrer. “The rapid-onset multi-variant booster response with CiVax™ in a heterologous or mixed prime-boost approach further supports the broad-spectrum utility of our vaccine candidate. Our work with CiVax™ emerged from our ongoing efforts to develop heat-stable, single-vial format vaccines for filoviruses. The ability to rapidly pivot from filoviruses, like Ebola, to SARS-CoV-2 demonstrates the broad applicability of this novel platform and our productive collaboration with Soligenix. A single-vial subunit vaccine that can be shipped at ambient temperatures and then needs only to be reconstituted with sterile water immediately prior to use has the potential to improve vaccination efforts globally by simplifying storage and distribution logistics not only as a stand-alone vaccine, but also as a practical add-on booster in persons previously vaccinated with other COVID-19 vaccines.”

“Our ThermoVax^® platform has successfully thermostabilized vaccines for ricin toxin, for filoviruses such as Ebola, Sudan and Marburg, and for COVID, and as such is a well-established thermostabilization strategy that enhances the standard protein subunit vaccination technology. We believe this enhancement makes protein subunit vaccines, the gold standard for safe vaccines, competitive with other vaccine technologies, such as mRNA, which have much more stringent cold-storage requirements,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “The ability of CiVax™ to induce rapid broad immune coverage, including against SARS-CoV-2 variants, even when administered after other primary vaccination series, is another marked advantage. Moreover, the use of subunit vaccines that has been built on years of proven vaccine technology may also provide a very safe option for people of all ages. This platform may also aid in the preparation for future pandemics.”

About CiVax™

CiVax™ is the Company’s heat stable subunit vaccine candidate for the prevention of COVID-19, the infection caused by SARS-CoV-2. Under the Company’s Public Health Solutions business segment, ongoing collaborations with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaiʻi at Mānoa have demonstrated the feasibility of developing heat stable subunit filovirus vaccines, including hemorrhagic disease caused by Zaire ebolavirus, Sudan ebolavirus as well as Marburg marburgvirus, with both monovalent and bivalent vaccine combinations. Formulation conditions have been identified to enable heat stabilization of each antigen, alone or in combination, for at least 12 months at 40 degrees Celsius (104 degrees Fahrenheit). Soligenix and its collaborators expanded the technology platform to assess compatibility with vaccine candidates targeting SARS-CoV-2, the cause of COVID-19.

CiVax™ has been previously demonstrated to be heat-stable for at least one year when formulated as a lyophilized single vial dose and reconstituted immediately prior to use with water for injection. Previous efficacy studies have demonstrated the novel protein antigen and adjuvant (CoVaccine HT™) combination yields broad spectrum immune responses in mice and in non-human primates. This subunit vaccine has also shown efficacy as a booster after other primary vaccinations against COVID and in particular, appears to yield broad immune coverage.

CiVax™ development was partially funded under a non-dilutive $1.5 million Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) awarded to Soligenix in December 2020.

About Coronavirus Infection

Coronavirus infections can cause a wide spectrum of disease in humans, ranging from a common cold to a more severe respiratory infection, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), which have a case mortality rate of approximately 10% and 30%, respectively. Similar to filoviruses, coronaviruses also are endemic in wildlife populations and can be transmitted to humans with close contact. The COVID-19 outbreak, caused by SARS-CoV-2, is the most recent example of a suspected species crossover seen with this virus family. COVID-19 has been declared a global pandemic by the World Health Organization. The global impact of this emerging infection demonstrates the urgent need for robust technology platforms to rapidly develop new vaccines for novel diseases. Despite vaccines approved under Emergency Use Authorization, the logistical challenges of cold chain distribution and manufacturing scale up limited the ability to vaccinate individuals worldwide, a requirement to curtail further viral mutations and rapidly stop the pandemic.

About John A. Burns School of Medicine, University of Hawaiʽi at Mānoa

Established in 1965, the John A. Burns School of Medicine (JABSOM) is one of the degree-granting schools of the University of Hawaiʻi at Mānoa. Named in honor of the visionary former governor, JABSOM trains the next generation of outstanding physicians, scientists, medical technologists, and speech pathologists to improve the health and wellness of our diverse communities throughout Hawaiʻi and the Pacific. Our impactful research focuses on understanding and addressing health disparities, particularly in Native Hawaiian, Pacific Islander, and Filipinos. JABSOM is home to the first clinical department in an accredited medical school in the nation that is focused on health disparities of an indigenous population, Native Hawaiians.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet’s Disease.

Our Public Health Solutions business segment includes development programs for RiVax^®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax^®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company’s website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.

This press release may contain forward-looking statements that reflect Soligenix’s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment, the expected timing for closing the offering described herein and the intended use of proceeds therefrom. Statements that are not historical facts, such as “anticipates,” “estimates,” “believes,” “hopes,” “intends,” “plans,” “expects,” “goal,” “may,” “suggest,” “will,” “potential,” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, and include the expected amount and use of proceeds from the offering and the expected closing date of the offering. Soligenix cannot assure that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA’s concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Additionally, despite the biologic activity observed in aphthous ulcers induced by chemotherapy and radiation, there can be no assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behçet’s Disease. Further, there can be no assurance that RiVax^® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax^®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, Soligenix’s reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

View original content to download multimedia:https://www.prnewswire.com/news-releases/soligenix-announces-publication-demonstrating-civax-booster-induces-rapid-broad-protection-against-covid-19-variants-302410283.html

SOURCE SOLIGENIX, INC.

PHILADELPHIA
, March 25, 2025 /PRNewswire/ —

FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, was named a 2025 CIO 100 Award Winner by Foundry’s CIO. For almost 30 years, the CIO Awards have recognized innovative organizations that exemplify the highest level of strategic and operational excellence in IT. This award recognizes FMC’s Arc™ farm intelligence platform as an innovative way to deliver business and customer value in agriculture.

Arc™ farm intelligence is an integrated global crop protection platform developed to enable growers to proactively manage pests in their fields. The platform uses the power of real-time data and predictive modeling to help ensure the right crop protection products are applied precisely where and when they are needed. Insect management is the cornerstone of the Arc™ farm intelligence platform. The platform combines pest quantification, historical and forecasted weather data and crop health indicators, providing growers with reliable insights about their current and future pest pressure with up to 90% accuracy.

“This recognition honors our precision ag team’s exceptional ability to address grower challenges with cutting-edge digital solutions that enhance operational efficiency,” said Andi Le, chief digital officer. “The platform’s innovative pest identification capabilities and predictive modeling showcase the unique intersection of digital expertise and agronomic knowledge. We are incredibly proud of how the team leveraged digital innovation and deep agricultural understanding to deliver meaningful value for our customers.”

Arc™ farm intelligence delivers business value for growers by creating on-farm efficiency through enhanced scouting. This helps promote the sustainable use of FMC’s crop protection products, helps lower growers’ input costs and improves pest management outcomes.

“The CIO 100 Awards recognize IT leaders who drive innovation, transformation, and business success through technology. With an exceptionally high caliber of submissions each year, winning a CIO100 Award is a true honor, highlighting the bold vision, strategic excellence, and groundbreaking impact of the most influential CIOs shaping the future of digital enterprise,” stated Elizabeth Cutler, Content Director, CIO 100 Symposium & Awards. A highlight of the event each year is when a new CIO class is inducted into the prestigious Hall of Fame. These executives have advanced the field through their work, their community involvement, and their focus on mentoring the next generation of IT leaders. I am honored to celebrate these accomplishments and showcase what IT innovation and exceptional leadership look like.”

Since its launch in 2020, Arc™ farm intelligence has expanded from two countries to over 30. It now boasts nearly 65 pest predictive models and monitors over 55 insect types, providing growers with a vital tool to help them make informed decisions around pest management. FMC is exploring new features and integrations to continue to support growers across the globe, including insect mating disruption and growing degree day features. To learn more about Arc™ farm intelligence, visit fmc.com/arc-farm-intelligence.

Executives from the winning companies will be recognized at the CIO 100 Symposium & Awards, which takes place August 11-13, 2025. Additional information on the event can be found at event.foundryco.com/cio100-symposium-and-awards/awards/.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC’s innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn^®.

About CIO

CIO focuses on attracting the highest concentration of enterprise CIOs and business technology executives with unparalleled peer insight and expertise on business strategy, innovation, and leadership. As organizations grow with digital transformation, CIO provides its readers with key insights on career development, including certifications, hiring practices and skills development. The award-winning CIO portfolio provides business technology leaders with analysis and insight on information technology trends and a keen understanding of IT’s role in achieving business goals. CIO is published by Foundry, company information is available at www.foundryco.com.
Follow CIO on X: @CIOonline@CIOEvents #CIO100 #CIOHOF
Follow CIO on LinkedIn
Follow CIO on Facebook

About the US CIO 100 Awards
The annual US CIO 100 Awards celebrate 100 organizations and the teams within them that use IT in innovative ways to deliver business value, whether by creating competitive advantage, optimizing business processes, enabling growth, or improving relationships with customers. The award is an acknowledged mark of enterprise excellence.

Coverage of the 2025 US CIO 100 award-winning projects will be available online at www.cio.com in the weeks and months leading up to the event.

Arc is a trademark of FMC Corporation and/or an affiliate. Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fmc-corporation-named-2025-cio-100-award-winner-for-arc-farm-intelligence-302409883.html

SOURCE FMC Corporation

Stock Symbol: AEM (NYSE and TSX)

TORONTO
, March 25, 2025 /PRNewswire/ – Agnico Eagle Mines Limited (NYSE: AEM) (TSX: AEM) (“AgnicoEagle” or the “Company“) today announced that it will release its first quarter 2025 results on Thursday, April 24, 2025, after normal trading hours. Additionally, the Company will host its Annual and Special Meeting of Shareholders (the “AGM”) the following day, Friday, April 25, 2025, in a hybrid format (in Toronto and virtually).

First Quarter 2025 Results Conference Call and Webcast

Agnico Eagle’s senior management will host a conference call on Friday, April 25, 2025, at 08:30 AM (E.D.T.) to discuss the Company’s financial and operating results.

Via Webcast:

To listen to the live webcast of the conference call, you may register on the Company website at www.agnicoeagle.com, or directly via the link here.

Via Phone:

To join the conference call by phone, please dial 416.945.7677 or toll-free 1.888.699.1199 to be entered into the call by an operator. To ensure your participation, please call approximately five minutes prior to the scheduled start of the call.

To join the conference call without operator assistance, you may register your phone number here 30 minutes prior to the scheduled start of the call to receive an instant automated call back.

Replay Archive:

Please dial 289.819.1450 or toll-free 1.888.660.6345, access code 36377 #. The conference call replay will expire on May 25, 2025.

The webcast, along with presentation slides, will be archived for 180 days on the Company’s website.

Annual Meeting

The AGM will begin on Friday, April 25, 2025 at 11:00 AM (E.D.T). During the AGM, management will provide an overview of the Company’s activities.

Hybrid Format

The AGM will be held in person at the Arcadian Court, 401 Bay Street, Simpson Tower, 8^th Floor, Toronto, Ontario, M5H 2Y4 and online at: https://meetnow.global/M59UWL4

The Company is conducting a hybrid meeting that will allow registered shareholders and duly appointed proxyholders to participate both online and in person. The Company is providing the virtual format to provide shareholders with an equal opportunity to attend and be heard at the AGM even if they are unable to attend the AGM in person.

For details explaining how to attend, communicate and vote virtually at the AGM please see the Company’s Management Information Circular dated March 24, 2025, filed under the Company’s profile on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov. Shareholders who have questions about voting their shares or attending the AGM may contact Investor Relations by phone at 416.947.1212, by toll-free phone at 1.888.822.6714 or by email at [email protected] or may contact the Company’s strategic shareholder advisor and proxy solicitation agent, Laurel Hill Advisory Group, by phone at 1.877.452.7184 (toll free in North America), at 1.416.304.0211 (for collect calls outside of North America) or by e-mail at [email protected].

Investor Relations

Agnico Eagle Mines Limited
145 King Street East, Suite 400
Toronto, Ontario, M5C 2Y7
[email protected] 
Phone: 416.947.1212
Fax: 416.367.4681

About Agnico Eagle

Agnico Eagle is a Canadian based and led senior gold mining company and the third largest gold producer in the world, producing precious metals from operations in Canada, Australia, Finland and Mexico, with a pipeline of high-quality exploration and development projects. Agnico Eagle is a partner of choice within the mining industry, recognized globally for its leading sustainability practices. Agnico Eagle was founded in 1957 and has consistently created value for its shareholders, declaring a cash dividend every year since 1983.

View original content to download multimedia:https://www.prnewswire.com/news-releases/agnico-eagle-provides-notice-of-release-of-first-quarter-2025-results-conference-call-and-annual-meeting-302409463.html

SOURCE Agnico Eagle Mines Limited